Quantum BioPharma Ltd. (NASDAQ: QNTM) is moving its experimental multiple sclerosis drug Lucid-MS into a randomized, double-blind, placebo-controlled Phase 2 clinical trial following clearance from the U.S. Food and Drug Administration of its Investigational New Drug application. The FDA’s decision allows the company to proceed with human testing of a therapy that takes a different approach to treating MS, a chronic disease in which the immune system attacks the protective myelin sheath around nerve fibers.
Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2). Rather than broadly suppressing the immune system, as many existing MS therapies do, Lucid-MS is designed to target demyelination directly. The drug has been shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Phase 2 trial will evaluate the drug’s safety and efficacy in patients with MS.
The FDA clearance marks a significant step for Quantum BioPharma, which is dedicated to developing treatments for challenging neurodegenerative and metabolic disorders as well as alcohol misuse disorders. Its wholly owned subsidiary, Lucid Psycheceuticals Inc., focuses on the research and development of Lucid-MS. If successful, Lucid-MS could offer a new mechanism of action for MS patients, potentially addressing the root cause of nerve damage rather than only modulating the immune response.
Quantum BioPharma is also collaborating with Massachusetts General Hospital and Harvard Medical School on research involving the [¹⁸F]3F4AP PET imaging tracer. This tracer is being evaluated as a method to visualize and measure demyelination, which could provide a valuable tool for assessing treatment effects in MS and other demyelinating conditions.
The company’s broader portfolio includes UNBUZZD(TM), a product for alcohol misuse that was spun out into Unbuzzd Wellness Inc. Quantum retains a 19.84% ownership stake in Unbuzzd and is entitled to royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains full rights to develop similar products for pharmaceutical and medical uses.
The announcement places Quantum BioPharma alongside other companies advancing therapies in areas of unmet medical need. Novartis AG recently received FDA approval for Pluvicto(R) in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. had its supplemental Biologics License Application for ENFLONSIA(TM) accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. initiated a Phase 2 trial of BRIUMVI(R) in adults with treatment-resistant schizophrenia, and Bristol-Myers Squibb Company reported positive Phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma.
For investors, the FDA clearance reduces regulatory risk and sets the stage for a key clinical milestone. The Phase 2 trial will be closely watched as an indicator of whether Lucid-MS can translate its preclinical promise into a viable therapy for multiple sclerosis. If the trial succeeds, Quantum BioPharma could become a notable player in the MS treatment landscape. The full press release is available at https://ibn.fm/lCey9, and company updates can be found at https://ibn.fm/QNTM.
